Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Lung and Thoracic Cancers

Clinical Trials for Lung Cancers

24 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Lung

VICCTHO0398

12/04/2003

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Diagnostic

Lung
Miscellaneous

VICCTHO1078

04/12/2011

Nashville Early Diagnosis Lung Cancer Project

Other

Lung

VICCTHO1496

04/03/2015

Lung Cancer Screening Program at VICC: Correlative Study

Treatment

Lung

VICCTHO1499

04/23/2015

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung

CTSUTHOS1400

01/20/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

Treatment

Esophageal
Head/Neck
Lung

VICCHN1464

11/14/2014

A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck, Lung or Esophagus.

Treatment

Lung

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Treatment

Lung

ECOGTHO2511-M

11/04/2014

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Treatment

Lung

VICCTHO1467

10/02/2014

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Treatment

Lung

VICCTHN13111

08/27/2014

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Treatment

Lung

VICCTHO1415

08/27/2014

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Treatment

Lung

THOMK3475-024-M

08/05/2014

MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Treatment

Lung

VICCTHO1429

08/05/2014

An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Treatment

Lung

VICCTHO1444

08/05/2014

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-Line Therapy

Treatment

Lung
Non Small Cell

VICCTHN1332

07/18/2014

A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Treatment

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

Lung
Non Small Cell

VICCTHN12106

03/12/2014

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Lung
Non Small Cell

ECOGTHNE5508

06/29/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

Lung

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

Treatment

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Treatment

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)